Phase 3 Clinical Trial Evaluating Continu... - Cure Parkinson's
Phase 3 Clinical Trial Evaluating Continuous Subcutaneous Carbidopa/Levodopa (ND0612) Initiated In The United States For Parkinson's Disease
Written by
Farooqji
To view profiles and participate in discussions please or .
Read more about...
2 Replies
•
ND0612 update:
Phase 3 Trial of Investigational Parkinson Treatment ND0612 Initiated. Subcutaneous levodopa.
neurologylive.com/clinical-...
Thank you for posting this. I've been following Neuroderm for several years but had not seen this.
Not what you're looking for?
You may also like...
ANNOVIS BIO ANNOUNCES POSITIVE FDA NOTICE FOR BUNTANETAP PHASE 3 CLINICAL TRIAL IN PARKINSON'S DISEASE
https://irpages2.eqs.com/websites/annovis/English/431010/us-press-release.html?airportNewsID=e4e0b40
Bilateral Pallidothalamic Tractotomy (PTT) Clinical Trials in the United States
This is an encouraging sign of progress for those of us who are following the potential of Focused...
Starting phase 2 trial : Terazosin for Parkinson's Disease (TZ-PD)
Things are moving fast. A Phase II clinical trial for Terazosin in Parkinsons is already being...
Annovis Bio Announces Approval for EU Clinical Trial Sites for the Phase 3 Study of Buntanetap for the Treatment of Parkinson's Disease
This trial is already open in the United States, and I believe some on this forum are...
ANNOVIS BIO ANNOUNCES POSITIVE FDA FEEDBACK FOR BUNTANETAP PHASE 3 CLINICAL DEVELOPMENT IN PARKINSON'S DISEASE (ANVS401)
https://irpages2.eqs.com/websites/annovis/English/431010/us-press-release.html?releaseID=111474&d=20
Related Posts
Anyone participating in the Buntanetap Phase 3 trial?- MRI-Focused Ultrasound Undergoing Phase 3 Clinical Trial for Parkinson’s Treatment
- The naturally occurring molecule N-acetylcysteine (NAC) shows benefit in a clinical trial for Parkinson's Disease.
I was selected for a clinical trial in Phase 2, for a Mesenchymal Stem Cell Therapy for Parkinson's Disease. Looks promising, any thoughts?- Parkinson’s Disease Drug Therapies in the Clinical Trial Pipeline: 2020
